Philippos Costa, MD
Assistant Professor of Medicine (Medical Oncology and Hematology)DownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor of Medicine (Medical Oncology and Hematology)
Positions outside Yale
Scientific-Advisor, Medical Oncology, Associação Tumor Desmoide Brasil
Biography
Philippos A. Costa, M.D., is an Oncologist at Yale University. He received his medical degree from the Universiade Federal do Vale do Sao Francisco, Brazil, and completed two internal medicine residencies; at the Universidade Federal de Uberlandia and at the University of Miami Miller School of Medicine, and his fellowship at Yale University. He is an expert in Early Developmental Therapeutics as well as Sarcomas, including angiosarcomas, chondrosarcomas, leiomyosarcoma, GIST, and desmoid tumors.
Last Updated on July 10, 2025.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Early Phase Clinical Trial Program
- Internal Medicine
- Medical Oncology and Hematology
- Sarcoma Program
- Yale Medicine
Education & Training
- MS
- Yale, Internal Medicine (2025)
- Internal Medicine
- University of Miami (2022)
- Internal Medicine
- Universidade Federal de Uberlândia: (2018)
- MD
- Universidade Federal do Vale do São Francisco, Medicine (2016)
Research
Copy Link
Overview
• Dr. Costa described the association of desmoid tumors with breast implants and the comparative efficacy of different systemic therapies in desmoid tumors
• Along with his colleagues, Dr. Costa described the genetic landscape of angiosarcoma, along with its implications for immunotherapy strategies
• Dr. Costa described how dose escalation of ripretinib can lead to further benefits for GIST patients in a real-world scenario.
ORCID
0000-0001-9681-0515- View Lab Website
Ishizuka Lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Philippos Costa's published research.
Publications Timeline
A big-picture view of Philippos Costa's research output by year.
Jeffrey Ishizuka, MD, DPhil
Curtis Jamison Perry, MD, PhD
Hari Deshpande, MD
Kelly Olino, MD, FACS
Kurt Schalper, MD, PhD
Andrew Haims, MD
58Publications
226Citations
Publications
2025
Kaposi sarcoma incidence and mortality trends and disparities in the United States
Raja A, Costa P, Junejo M. Kaposi sarcoma incidence and mortality trends and disparities in the United States. Infectious Agents And Cancer 2025, 20: 80. PMID: 41189007, PMCID: PMC12584236, DOI: 10.1186/s13027-025-00710-x.Peer-Reviewed Original ResearchConceptsAge-adjusted incidence ratesKS incidenceHighest age-adjusted incidence ratesBlack menPublic health effortsCDC WONDER databaseAntiretroviral therapyKS casesKaposi's sarcoma incidenceBetween-group differencesMortality trendsHIV careWONDER databaseUnited StatesHealth effortsAIDS-defining illnessCombination antiretroviral therapyIncidence rateSex disparitiesHuman herpesvirus 8Between-groupSarcoma incidenceAAMRDeath countsWhite men907 Midkine suppresses interferon-driven antigen presentation and dendritic-cell activation in neuroendocrine tumors
Wang J, Perry C, Frey A, Fei Y, Costa P, Ghadermarzi S, Levine D, Ishizuka J. 907 Midkine suppresses interferon-driven antigen presentation and dendritic-cell activation in neuroendocrine tumors. 2025, a1027-a1027. DOI: 10.1136/jitc-2025-sitc2025.0907.Peer-Reviewed Original ResearchDecoding the Epigenome: Comparative Analysis of Uterine Leiomyosarcoma and Leiomyoma
Pfaff M, Costa P, Tang H, Sailo B, Sharma A, Ahuja N. Decoding the Epigenome: Comparative Analysis of Uterine Leiomyosarcoma and Leiomyoma. Cancers 2025, 17: 2610. PMID: 40867239, PMCID: PMC12384543, DOI: 10.3390/cancers17162610.Peer-Reviewed Original ResearchCitationsConceptsUterine leiomyosarcomaUterine leiomyomaSmooth muscle tumorsClass I expressionTherapeutic targetDysregulation of signaling pathwaysHistone deacetylasesGlobal DNA hypomethylationMuscle tumorsExtracellular matrix accumulationPotential therapeutic targetTumor typesTumor pathogenesisHistone acetyltransferase activityI expressionClinical managementTumorWnt/b-cateninDNA hypomethylationPathway dysregulationMatrix accumulationDiagnostic biomarkersEpigenetic profilesMethylation patternsEpigenetic landscapePALB2 c.3106G>C (p.Val1036Leu) in a familial cancer setting suggesting potential pathogenicity
Costa P, Hardy N, LoRusso P. PALB2 c.3106G>C (p.Val1036Leu) in a familial cancer setting suggesting potential pathogenicity. BMJ Case Reports 2025, 18: e266362. PMID: 40750108, DOI: 10.1136/bcr-2025-266362.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsHistory of cancerPALB2Prostate cancerAssociated with homologous recombination deficiencyDNA damage repair gene mutationsNo historyHomologous recombination deficiencyLoss of heterozygosityNo history of cancerHeterozygous germline variantsOvarian cancerRepair gene mutationsRecombination deficiencyBreast cancerGermline variantsGene mutationsPathogenic roleCancer historyCancer settingCancerSomatic analysisProstateMultiple cancer diagnosesCancer diagnosisAgeDNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas
Statz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, Espejo-Freire A, Coelho P, Costa P, D’Amato G, Jonczak E, Trent J, Montgomery E, Lombard D, Rosenberg A, Dhir A. DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Cancers 2025, 17: 1962. PMID: 40563612, PMCID: PMC12191036, DOI: 10.3390/cancers17121962.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDDR alterationsPathway alterationsConclusions:T cell inflamed scorePD-L1+DNA damage responseShorter overall survivalPD-L1Histological subtypesOverall survivalYoung adultsTherapeutic optionsRare cancersAdult sarcomasSarcoma subtypesImmune markersGene expression profilesMalignant progressionMolecular profilingPatient samplesBiomarker associationsSarcomaTumorSubtypesGenomic instabilityTranscriptomic landscape of Kaposi sarcoma: Insights into therapeutic targeting of KSHV.
Fei Y, Costa P, Junejo M, Li M, Perry C, Damsky W, Ishizuka J. Transcriptomic landscape of Kaposi sarcoma: Insights into therapeutic targeting of KSHV. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23526.Peer-Reviewed Original ResearchConceptsKaposi's sarcoma herpesvirusKaposi's sarcomaTranscripts Per MillionKSHV genomeHIV statusPresence of Kaposi’s sarcoma herpesvirusDisease progressionLatency-associated regionExpressed genesHistory of organ transplantationVirus-associated tumorsTherapeutic targetFormalin-fixed paraffin-embedded (FFPEGene expressionParaffin-embedded (FFPEHuman herpesvirus 8Differential gene expression analysisDisseminated diseaseViral eradicationViral gene expressionHIV-positiveBaseline characteristicsHHV-8Gene expression analysisTumor morphologyA phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
Costa P, Pilat M, Rodon Ahnert J, Burgess M, Tinoco G, Close J, Groisberg R, Subbiah V, Powers B, Haddox C, Grilley-Olson J, Keedy V, Li J, Ivy S, Patel A, Shapiro G, Ishizuka J, Schalper K, LoRusso P. A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors. Journal Of Clinical Oncology 2025, 43: 3087-3087. DOI: 10.1200/jco.2025.43.16_suppl.3087.Peer-Reviewed Original ResearchConceptsProgression-free survivalSolid tumorsOverall survivalClinical benefitOpen-label phase II clinical trialSolid tumors refractory to standard treatmentMedian progression-free survivalRefractory to standard treatmentIDH mutant tumorsPhase II clinical trialBRCA-mutated cancersEfficacy of olaparibPhase 2 studyPhase II trialFollow-up timePre-clinical dataII clinical trialsPre-clinical evidenceImpaired homologous recombinationClinical Trials NetworkAdvanced chondrosarcomaMedian OSII trialIDH1/2 mutationsMedian ageTreatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation.
Yi I, Gomes P, Hardy N, Rose B, Yu-Cherng C, Bialick S, Jonczak E, D'Amato G, Deshpande H, Carmagnani Pestana R, David B, Trent J, Campos F, Costa P. Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation. Journal Of Clinical Oncology 2025, 43: 11562-11562. DOI: 10.1200/jco.2025.43.16_suppl.11562.Peer-Reviewed Original ResearchConceptsDesmoid tumorsMedian TFSPatients treated with sorafenibMulti-institutional retrospective analysisPalmar-plantar erythrodysesthesia syndromeSide effectsDuration of sorafenib treatmentDuration of systemic therapyFuture treatmentPatient stopped therapyOutcomes of patientsLog-rank testKaplan-Meier curvesTime of discontinuationFactors associated with better outcomesMonths of durationProgression of diseaseDiscontinued sorafenibSorafenib discontinuationSorafenib useStable diseasePartial responseDiscontinued therapySystemic therapyTreatment discontinuationA phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors.
Costa P, Hafez N, Pilat M, Kalyan A, Azad N, Gore S, Shields A, Al Hallak M, Jin N, Malalur P, Hays J, Rodon Ahnert J, Schalper K, LoRusso P. A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors. Journal Of Clinical Oncology 2025, 43: 3089-3089. DOI: 10.1200/jco.2025.43.16_suppl.3089.Peer-Reviewed Original ResearchConceptsProgression-free survivalSolid tumorsOverall survivalClinical benefitOpen-label phase II clinical trialSolid tumors refractory to standard treatmentMedian progression-free survivalRefractory to standard treatmentNational Clinical Trials NetworkPhase II clinical trialCombination of olaparibEfficacy of olaparibLow-grade tumorsLower-grade tumorsPhase 2 studyNCI's National Clinical Trials NetworkFollow-up timePre-clinical dataII clinical trialsIsocitrate dehydrogenase mutationPre-clinical evidenceClinical Trials NetworkMedian OSStable diseaseImpaired homologous recombination repairPerturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas.
Perry C, Frey A, Fei Y, Costa P, Wang J, Ghadermarzi S, Levine D, Koda A, Nassar A, Ding M, Nie Y, Cordero-Dumit T, Augert A, van Djik D, Olino K, Ishizuka J. Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas. Journal Of Clinical Oncology 2025, 43: 2520-2520. DOI: 10.1200/jco.2025.43.16_suppl.2520.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerMerkel cell carcinomaMonocyte-derived DCCD14+ monocytesT cellsPatient tumorsResponse to IFNImpact of immune checkpoint blockadeTumor-infiltrating T cellsCo-CultureSmall cell lung carcinomaTumor immunity cycleImmune checkpoint blockadeImmune cells co-culturedCell lung carcinomaInnate immune signaturesHuman tumor specimensCell lung cancerLymph node metastasisCell linesFactors associated with responseLong-term survivalAssociated with nonresponseStandard of careImmune samples
Academic Achievements & Community Involvement
Copy Link
Activities
activity GIST Journal
07/01/2021 - PresentPeer Review Groups and Grant Study SectionsRevieweractivity Managed Health Care
2022 - PresentMedia PresenceResearcherDetailsFeatured in magazine article entitled “Black Lung Cancer Patients May Be Missing Out On Era of Targeted Therapy” based on the work “Prevalence of Targetable Mutations in Black Patients"activity American Society of Clinical Oncology (ASCO)
02/01/2018 - PresentProfessional OrganizationsMemberactivity American College of Physicians (ACP)
2018 - PresentProfessional OrganizationsMemberactivity Sociedade Brasileira de Oncologia Clínica (SBOC)
2018 - PresentProfessional OrganizationsMember
Honors
honor The Vanessa Blumer Research Scholar Award
06/30/2022Regional AwardDetailsUnited States
Clinical Care
Copy Link
Overview
Clinical Specialties
Sarcoma; Medical Oncology
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
Get In Touch
Copy Link
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.